Form 8-K - Current report:
SEC Accession No. 0001213900-24-097894
Filing Date
2024-11-14
Accepted
2024-11-14 09:25:16
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221143-8k_abvcbio.htm   iXBRL 8-K 26883
2 PRESS RELEASE ea022114301ex99-1_abvcbio.htm EX-99.1 32386
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6139
  Complete submission text file 0001213900-24-097894.txt   250281

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20241114.xsd EX-101.SCH 3021
5 XBRL LABEL FILE abvc-20241114_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abvc-20241114_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0221143-8k_abvcbio_htm.xml XML 3570
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 241457751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)